Nitrous oxide (N 2 O) is one of the oldest drugs still in use in medicine. Despite its superior pharmacokinetic properties, controversy remains over its continued use in clinical practice, reflecting in part significant improvements in the pharmacology of other anaesthetic agents and developing awareness of its shortcomings. This narrative review describes current knowledge regarding the clinical use of N 2 O based on a systematic and critical analysis of the available scientific literature. The pharmacological properties of N 2 O are reviewed in detail along with current evidence for the indications and contraindications of this drug in specific settings, both in perioperative care and in procedural sedation. Novel potential applications for N 2 O for the prevention or treatment of chronic pain and depression are also discussed. In view of the available evidence, we recommend that the supply of N 2 O in hospitals be maintained while encouraging its economic delivery using modern low flow delivery systems. Future research into its potential novel applications in prevention or treatment of chronic conditions should be pursued to better identify its role place in the developing era of precision medicine.
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The discovery of nitrous oxide in 1772 is usually attributed to Joseph Priestley, an English cleric and chemist. A key step in this discovery was the use of an experimental tool designed by Stephen Hales in the early 1700s to collect gas over water. Priestley used this apparatus to discover a host of gases among which were nitric oxide (NO), nitrous oxide (N 2 O), and oxygen (O 2 ). In 1775 he described his findings in his book, Experiments and Observations on Different Kinds of Air. Priestley did not recognise its potential anaesthetic properties and moved to other investigations.
In 1798, Thomas Beddoes founded the Pneumatic Medical Institution in Bristol, England in order to study the use of gases in medicine. Humphry Davy was appointed Laboratory Superintendent of the institute and experimented with N 2 O inhalation, conducting many experiments on himself. 1e3 Aside from its analgesic effects, Davy observed that patients who had inhaled N 2 O showed a state of euphoria. He proposed the term 'laughing gas' as an alternative name for N 2 O, and started to demonstrate its exhilarating effects at meetings with his friends. In his book, Researches, Chemical and Philosophical; Chiefly Concerning Nitrous Oxide or Dephlogisticated Nitrous Air and Its Respiration, which was published in 1800, he extensively described the history, chemistry, physiology, and recreational use of N 2 O. It is only at the end of his book that he makes a statement about the possible use of N 2 O during surgery: 'As nitrous oxide appears capable of destroying physical pain, it may probably be used with advantage during surgical operations'.
Nevertheless, this potential application did not reach the surgical profession, and for the next 40 yr surgical interventions continued to be performed without anaesthesia. In both America and England, the compound was used as a party drug at 'laughing gas' frolics or it was inhaled for public entertainment. It was only in December 1844, after Gardner Colton demonstrated the analgesic properties of N 2 O at a popular meeting, that dental surgeon Horace Wells considered the possibility of using the compound for painless tooth extraction. After several successful experiments in his private practice, Wells decided to give a public demonstration at the Massachusetts General Hospital in Boston, USA. However, the gas was improperly administered and the patient experienced pain, making this demonstration a fiasco. In the meantime, ether was successfully introduced as an anaesthetic agent in 1846 by William Morton. It took another two decades before Colton revived the use of N 2 O in the USA, and later demonstrated N 2 O anaesthesia at the 1867 International Exhibition in Paris, France. 4, 5 By 1870, N 2 O pressure cylinders became available. Its use with air meant that cyanosis occurred routinely. Soon thereafter, mixtures with oxygen became available, resulting in safer administration of N 2 O. As a consequence, use of the compound gained wide acceptance in dentistry, obstetrics, and during general anaesthesia in combination with other anaesthetic agents. Its cited advantages included its analgesic and amnestic properties, rapid induction and recovery characteristics, a decreased need for other anaesthetic agents, and its non-flammability. 6 The mechanisms of action of N 2 O have been reviewed by Sanders and colleagues. 7 N 2 O remained a popular anaesthetic until the last quarter of the 20th century. From the mid-1950s concerns were expressed about its potential toxic effects, 7, 8 shortly followed by reports on the potential risks of occupational exposure and environmental effects. 9e12 Reports of complications and fatalities related to mistakes in N 2 O supply systems 13 further spurred the opinion that N 2 O should be abandoned. Since then, the place of N 2 O in anaesthetic practice has been continuously challenged, leading to sometimes heated debates between advocates and opponents.
14e17
A recent meta-analysis of 35 randomised clinical trials showed no differences in the in-hospital fatality rates of N 2 Obased and N 2 O-free anaesthesia techniques, but suggested that N 2 O may be avoided in patients with pre-existing poor pulmonary function or at high risk for postoperative nausea and vomiting (PONV). 18 Nevertheless, unsolved controversies on the use of N 2 O still exist both in and outside of the operating theatre. Therefore, in 2014, the European Society of Anaesthesiology convened a Task Force to provide expert opinionbased recommendations on the uses of N 2 O in various clinical settings. The present narrative review, including both randomised trials and observational studies, stems from this effort to define evidence for the role of N 2 O in anaesthesia and analgesia based on a critical analysis of the available scientific literature on the topic over the past 10 yr (2004e14). This information may help identify patients who may benefit from use of N 2 O in their anaesthetic or analgesic treatment.
when no superior, broad evidence base could be discerned. We only included articles written in English. Figure 1 summarises the results of the study selection process.
Pharmacological aspects

Induction and wash-in
The unique combination of low solubilities in blood and other tissues makes N 2 O the fastest 'in/out' anaesthetic agent routinely available. N 2 O uptake in the lungs increases arterial blood concentrations of concomitantly administered 'second' gases (O 2 , potent inhaled anaesthetics). Perfusion-driven N 2 O uptake in lung units with lower ventilation/perfusion ratios generates a powerful alveolar concentrating effect on the accompanying second gases, which is most readily demonstrated when their arterial blood partial pressures are measured. 20e22 The effect translates clinically into faster 21 and smoother induction 23 and improved arterial oxygenation compared to when O 2 /air is used with an identical inspired O 2 concentration. 24 These effects on second gases are greatest during the initial high rate of uptake of N 2 O, but are also sustained to a lesser extent during the maintenance phase of anaesthesia.
21,24
Maintenance
During maintenance, N 2 O is always combined with other drugs because of its low anaesthetic potency. Its minimal alveolar concentration (MAC) is 105%, but provision of adequate oxygen delivery precludes administration of concentrations above 70e75%, thus limiting its use to 0.7 MAC. 25, 26 Because MAC is additive, the alveolar concentration of the potent inhaled anaesthetic can be reduced proportionally. 25 Fourth, the interaction for return of consciousness (MACawake) is infra-additive, further accelerating emergence. 41 Finally, the reverse second gas effect hastens emergence by accelerating wash-out of the potent inhaled anaesthetic from arterial blood, 22 the same principle responsible for the Fink effect (diffusion hypoxia) caused by the dilution of the partial pressure of O 2 in the alveoli. 42 The more rapid emergence with N 2 O has been illustrated in small clinical trials.
22,43
Quantitative aspects
Quantitative aspects of N 2 O anaesthesia remain poorly understood by many clinicians, especially where it is used at reduced fresh gas flows (FGFs). Although the use of an excessively high FGF during wash-in may diminish potential economies in agent usage, 44 low flow inhalational anaesthesia maintenance is increasingly popular because of considerations of cost and pollution (both in the operating room and environmental 
Contraindications and complications
Diffusion into air filled spaces
Because the solubility of N 2 O is higher than that of N 2 , N 2 O diffuses more rapidly and in higher amounts into closed airfilled cavities than N 2 diffuses out. High inspired N 2 O concentrations can therefore expand air-filled spaces such as a pneumothorax or intracranial air collection, potentially causing tension pneumothorax or intracranial hypertension. N 2 O is traditionally contraindicated in these circumstances. However, in a study of 24 craniotomy patients randomised to N 2 O cessation or continuation at dural closure, intracranial pressure was lower after operation in those where it was continued. 48 Nevertheless, pneumocephalus is universal after craniotomy and significant intracranial air can persist for up to 3 weeks, making use of N 2 O for repeat anaesthesia in this period potentially hazardous. 49 A similar contraindication exists if highly insoluble gases such as sulphur hexafluoride have been injected into the eye during or after intraocular and retinal surgery; N 2 O should not be used until complete resorption of these gasesdup to 3 months after surgery. 50 Diffusion into and out of the middle ear complicates tympanic membrane surgery and has been thought to contribute to postoperative nausea and vomiting (PONV). 51, 52 Distension of bowel may worsen postoperative pain, and has been proposed as a further contributing factor to N 2 O-related PONV, 53, 54 but the data are insufficient and inconclusive to give a recommendation. 55e62 There are mixed data from trials as to whether N 2 O use interferes with surgical conditions, particularly during laparoscopy. 62 
Absorption atelectasis
When breathing air, retention of insoluble N 2 in alveoli prevents collapse of poorly ventilated lung compartments. In lung units with very low ventilation/perfusion ratios, the rate of perfusion-driven uptake of soluble gas across the alveolarecapillary interface can exceed the ventilation rate of the compartment. This is the basis of absorption atelectasis, which is seen with oxygen breathing and N 2 Oeoxygen mixtures. 63 The ENIGMA (Evaluation of Nitrous oxide In the Gas Mixture in Anaesthesia) trial randomised 2050 patients having major surgery to either 70% N 2 Oe30% oxygen or 80% oxygen in air, and found an increased incidence of atelectasis on postoperative chest radiography or CT (13% vs 7.5%, P<0.001) in the N 2 Oeoxygen group. 64 Despite this, N 2 O actually improves oxygenation intraoperatively relative to an O 2 /air mixture with similar F I O 2 because of the ongoing second gas effect driven by N 2 O uptake in low V/Q lung compartments. 24 
Procedural pain management
The clinical use of N 2 O is associated with a limited range of side-effects (see Table 1 ). The risk of side-effects associated with its use as sole agent for procedural pain management has been assessed by surveys. In a 4 yr prospective survey, 35 942 data sheets were received from 191 French hospital paediatric (82%) and adult units (18%). Of the 1581 (4.4%) adverse events reported, the most common were gastrointestinal and neuropsychiatric disorders (86%), nausea/vomiting, and agitation/euphoria. 65 
Postoperative nausea and vomiting
Numerous studies have investigated the influence of N 2 O on PONV, most of which were severely underpowered. Several meta-analyses have found that N 2 O increases the risk of PONV, but with significant heterogeneity amongst studies. 66, 67 The overall relative risk increase is~20%. 68 Metaregression of data from these studies showed that the risk is related to duration of exposure to N 2 O, with no clinically significant increase in PONV incidence up to 75 min of exposure. Furthermore, data from the largest study investigating N 2 O and PONV found that it had no significant effect on rates of severe PONV (requiring more than two rescue doses of anti-emetic) in patients who were given routine intraoperative anti-emetic prophylaxis. 69 The independent effect of supplemental N 2 O on PONV in the setting of either inhalational or intravenous anaesthesia has been shown to be negligible when routine PONV prophylaxis is provided. 70 Toxicitydmethionine synthase N 2 O irreversibly oxidises the cobalt atom in cobalamin to inhibit the activity of the vitamin B 12 -dependent enzyme methionine synthase. Methionine synthase is vital for two important metabolic cycles 71 : the folate cycle (fundamental to DNA synthesis) and the S-adenosyl methionine (SAM) cycle (which generates methyl donor groups for a variety of synthetic functions and produces homocysteine as an intermediate metabolite). The degree of inactivation of methionine synthase by N 2 O is related to duration of exposure with a halftime of~45 min in humans. 72 In rodents, a teratogenic effect of N 2 O was shown for high concentrations (up to 75 vol%) over long periods (24 h ).
73,74
The negative effects associated with prolonged N 2 O sedation in severely diseased patients were described in 1956. 75 Toxicity depends on duration of exposure: continuous administration for 6 h did not cause any adverse effects, whereas 12 and 24 h exposures showed signs of bone marrow toxicity. 76 N 2 O exposure can precipitate a megaloblastic crisis or subacute combined degeneration of the spinal cord in vitamin B 12 or folate-deficient patients. Death has been reported with repeated exposure in a case of a rare congenital 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency. 77, 78 Patients with a common MTHFR gene variant (C677T) develop higher plasma homocysteine concentrations after N 2 O anaesthesia, 79 but these patients do not experience a higher incidence of cardiovascular events after N 2 O anaesthesia. 80 A high incidence of megaloblastic changes was reported in critically ill intensive care patients exposed to N 2 O for surgery before admission. Its routine use in anaesthesia for surgery in this at-risk population has long been discouraged. 81 
Toxicitydimmunosuppression and infection
These metabolic effects raised the important question whether N 2 O might interfere with immune function and increase the risk of postoperative infection. Fleischmann and colleagues 82 found no significant influence of N 2 O on wound infection rates in 418 patients undergoing elective colon resection. 82 In the ENIGMA trial, there was an increased incidence of wound infection (10% vs 7.7%, P¼0.036), postoperative fever (34% vs 28%, P¼0.003), and pneumonia (1.5% vs 3.0%, P¼0.04) in the N 2 Oeoxygen group compared with the N 2 O-free group. However, the larger ENIGMA 2 trial found no difference in surgical site infection rates (9% vs 9%, P¼0.61) or postoperative fever (15% vs 16%, P¼0.99) in 6992 patients undergoing major elective surgery. The primary difference between the two latter trials was the F I O 2 in the control group (80% in ENIGMA, 30% in ENIGMA 2). Although earlier studies suggested that a high F I O 2 may be protective from surgical site infection, 83 
Toxicitydoccupational exposure
The potential toxicity for health professionals and patients after N 2 O exposure is still a topic of debate. Occupational exposure has previously been linked to premature delivery and congenital malformations in the parturient. Studies on that topic are commonly of low methodological quality so that drawing clear conclusions is difficult. 7 A large US survey and clinical studies conducted in the 1970s suggested an increased rate of miscarriage, birth defects, and chronic health problems in female health workers exposed to anaesthetic gases in general.
87e89
A meta-analysis suggesting an increased rate of spontaneous abortion in female health workers exposed to anaesthetic gases used data before routine waste gas scavenging was used or from environments, such as dental practice, where these devices are not in use.
90e92 A large questionnaire study of members of the Swedish Midwives Association (n¼3358) 93 showed no relationship between exposure to N 2 O and likelihood of conception except for 41 midwives who attended more than 30 labours per month with use of N 2 O. In this study, scavenging systems for N 2 O were only partly used, and N 2 O exposure was estimated in the midwives without information about the occupational exposure limit. Thus, it remains unknown to what extent occupational exposure can contribute to toxicity for patients or health professionals, in particular for pregnant women. However, the potential toxicity has resulted in development of minimum occupational Safety and Health Administration standards. 94 Most countries have explicit Occupational
Exposure Limits (OELs) commonly expressed in Time Weighed Average (TWA) exposure during an 8 h working shift. The OELs differ somewhat but are in the range of 25e100 ppm. Recently, the effects of scavenging systems and the double face mask (DFM) were studied in paediatric pain control and in dental practice. The DFM system, with or without a demand valve (DV), connected to a portable evacuation system during N 2 O administration to children for painful procedures kept N 2 O levels within the local environment below recommended limits. In contrast, use of a normal face mask resulted in N 2 O concentrations above suggested limits. 95 In a study in paediatric dental practice, occupational exposure was within the recommended OEL in only 38% of cases, suggesting that optimisation of scavenging systems is needed. 96 In summary, available literature is not conclusive about the potential toxic effects in certain patient populations. With the emerging use of N 2 O in combination with O 2 for painful procedures, this topic has gained increasing interest. Recent studies demonstrate that use with scavenging systems can decrease occupational exposure to levels below the OEL. However, use in dental surgery requires adequate experience and use of scavenging systems to reduce the amount of occupational exposure below the commonly accepted threshold of 25e50 ppm. 97 Although there are only limited, low-quality data to clearly substantiate concerns regarding the reproductive toxicity of occupational exposure to N 2 O, appropriate scavenging and use of other techniques should be used routinely. 98 Moreover, it seems prudent to perform measurements of OEL regularly and to train healthcare providers in adequate use of scavenging systems.
Toxicitydcardiovascular and cerebrovascular outcomes
Several studies have shown that continual exposure to N 2 O in patients leads to progressive increase in plasma homocysteine levels after~1 h of anaesthesia, 99 which is associated with endothelial dysfunction in vivo. The ENIGMA trial found a nonsignificant increase from 0.7% to 1.3% (P¼0.26) in ischaemic cardiac complications within 30 days of surgery, and at 3 yr follow-up there was an increased incidence of late myocardial infarction in patients in the N 2 Oeoxygen group. 64 109 The currently used volatile anaesthetic agents also have potent greenhouse properties, but are released into the atmosphere in smaller quantities. Of the volatile agents, desflurane has the greatest longevity in the atmosphere, and desflurane anaesthesia produces comparable emissions to MAC equivalent combinations of sevoflurane or isoflurane with N 2 O. Low flow anaesthesia is an effective strategy to reduce inhalational agent consumption and release, and newer automated target-controlled gas delivery systems are likely to make routine use of low flow anaesthesia more achievable and efficient. These systems would potentially minimise the environmental effects of inhalational anaesthesia.
Procedural sedation
Adults There is no evidence to support the notion that a delivered concentration 50% of N 2 O should be the cut-off value for procedural sedation in children; N 2 O has been delivered at concentrations of 20e70% without reported major complications. Although there are no studies addressing fasting requirements, the majority of anaesthesia-related guidelines recommend 2 h of fasting for clear fluids before N 2 O administration. Guidelines from the British Dental Society do not recommend fasting before N 2 O administration. Despite the lack of evidence in the literature on airway patency during N 2 O sedation, several studies considered the risk of aspiration to be low, even in non-fasted paediatric patients.
110e112
There are no trials specifically on the use of N 2 O in burns treatment. Although a subgroup of patients in procedural sedation studies received N 2 O for burns, no subgroup analysis was reported. Based on safety issues related to repeated exposure to this drug and the risk of toxicity in the setting of dressing changes in burn patients, caution should be exercised when children are repeatedly exposed to N 2 O.
Evidence is limited regarding the effectiveness of using N 2 O in young children (<1 yr old), infants and neonates. Two studies were identified: (1) an RCT where the application of N 2 Oþtopical local anaesthetic (lidocaine/prilocaine 5% cream) for injection in children <1 yr old showed a significantly lower pain score when compared with local anaestheticþair or N 2 Oþplacebo cream 113 ; (2) a prospective open-label cohort study where N 2 O was successfully administered for tracheal intubation in preterm infants requiring surfactant therapy. 114 The recently released safety warning released by the US FDA 115 on the risk of potential neurotoxicity of anaesthetic drugs, including N 2 O, in children aged <3 yr places use of these medications under renewed scrutiny. Although the FDA statement is mainly based on animal and observational studies, the risk and benefit of general anaesthetic administration in young children needs to be carefully evaluated before their administration, and assessment of any potential long-term neurological effects awaits the findings of large randomised trials.
115
Dentistry Table 3 shows a summary of prospective trials on the use of N 2 O oxide in dentistry. The experimental paradigms are heterogeneous, for example inspired concentrations of N 2 O varied between 30% and 70%, and local anaesthetics were administered in all studies. Of 11 studies with a prospective cohort study design, only one was designed as a placebocontrolled trial. 116e118 This study showed no effect of 
Obstetrics
Until 2002, N 2 O was used as an analgesic in 50e75% of all parturients in the UK during labour, and in up to 60% in Finland. 125 Practice varies widely; in other parts of Europe N 2 O is either not used at all for this indication or only in specialised delivery clinics (e.g. The Netherlands). In contrast, women indicated higher sedation scores with remifentanil than with N 2 O. Although remifentanil seems to be preferable compared with epidural analgesia for analgesia, the large multicentre randomised controlled trial RAVEL (randomised study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) clearly demonstrated an unwanted side-effect profile for remifentanil, namely increased rates of nausea, vomiting, itching, and respiratory depression. 135 Compared with sevoflurane, N 2 O was shown to be inferior regarding pain relief, showed less sedation but induced more nausea and vomiting. 136 Several studies have assessed the analgesic efficacy of N 2 O during other obstetric procedures. N 2 O was shown to decrease the median level of pain in 450 women undergoing external cephalic version. 137 It is an effective alternative to infiltration anaesthesia to provide analgesia during genital tract suturing after childbirth. 138 N 2 O, however, did not reduce intra-or postoperative pain in women undergoing elective abortions by vacuum extraction when supplementing a paracervical block. Similarly, during suction evacuation for first trimester pregnancy termination under conscious sedation, applying N 2 O instead of air did not lead to differences in pain scores, postoperative side-effects, or satisfaction levels. 139 The most frequently observed side-effects of N 2 O are dizziness and nausea and vomiting, although nausea and vomiting also occur frequently in women without use of analgesics. 125 Talebi and colleagues 128 showed lower VAS pain scores during labour in 523 parturients using N 2 O vs of O 2 only, but the rate of side-effects such as nausea (8.4%), vomiting (2.3%), dizziness (22.6%), and drowsiness (15.4%) were all 125 and more effective than placebo or no treatment, but is not more effective than other analgesics. 126 Although N 2 O does not seem to have adverse influence on the delivery process and on extrauterine adaptation as measured by the Apgar score, there is still significant and ongoing controversy as to whether intrauterine exposure to anaesthetics has persistent adverse effects on neurocognitive function and psychosocial development. 142 The primary beneficial effects of N 2 O use in labour may be its anxiolytic effect and the parturient's sense of control that accompanies self-administration. These results should be interpreted with caution because the numbers of trials and their sample sizes are small, and there is an unclear risk of bias and the number trials of high methodological quality is small. N 2 O appears to remain a good option for analgesia during labour and as part of general anaesthesia for operative delivery provided that adequate boundary conditions are provided and the parturient is not willing or able to receive more invasive interventions for labour analgesia, such as epidural analgesia.
Efficacy of analgesia and anxiolysis in labour
Potential uses in chronic conditions
Given the potential safety issues related to repeated exposure to this drug, considerable caution is warranted in the design of studies and treatment protocols for the treatment of chronic conditions with N 2 O.
Chronic pain
There are no data available on the potential value of N 2 O in chronic pain therapy. However, there is evidence of a potential preventive effect of N 2 O anaesthesia on development of chronic pain after major surgery. A follow-up study of the ENIGMA 2 trial found no overall benefit except in patients from an Asian sub-population amongst whom specific polymorphisms of the tetrohydrofolate reductase enzyme system were more frequent. These phenotypes appeared to be more sensitive to the inhibitory effects of N 2 O on the methyl group donor activity of methionine synthase, leading to impaired DNA synthesis. Resulting impaired gene expression and reduced neuronal plasticity and neuro-inflammation 143 may inhibit the central nervous system sensitisation that leads to chronic post-surgical pain.
Major depression
The first in-human trial of N 2 O in treatment-resistant major depression was based on the surprising efficacy of ketamine in providing rapid antidepressant effects, 144 even in patients who had failed multiple antidepressant treatments, referred to as treatment-resistant depression. 145, 146 Ketamine and N 2 O are thought to exert their antidepressant action via inhibition of N-methyl-D-aspartate (NMDA)-type glutamate receptors. 147 In a double-blind proof-of-concept trial, 20 patients with treatment-resistant depression were randomised to 50% N 2 O/ 50% O 2 or placebo (50% O 2 ) for 1 h in a cross-over design with sessions separated by 1 week. Symptoms of depression improved significantly at 2 and 24 h after receiving N 2 O compared with placebo. Three patients (15%) had a full remission after N 2 O compared with none after placebo. In several patients, the antidepressant response to N 2 O was maintained at 1 week. 148 In a prospective study among 50
probands, those with a strong family history of alcohol problems had a significantly different subjective response to a 30 min inhalation session with 50% N 2 O/50% O 2 mix with a much higher stimulant response compared with patients without family history, a pattern that was previously observed with ketamine and is suggestive of a common NMDA-receptor dysregulation. 149 In a separate study, 25 healthy probands were randomised to either 50% N 2 O/50% O 2 or air and exposed to a laboratory model of psychological trauma to simulate post-traumatic stress disorder. Intrusive memory frequency was significantly reduced after N 2 O exposure compared with placebo, suggesting potential utility in post-traumatic stress disorder. 150 Although the current evidence for the use of N 2 O as a treatment in mood disorders is small, there is substantial interest in further exploring the potential utility of this novel approach in major psychiatric disorders.
Conclusions and Future Perspectives
N 2 O is the least soluble, fastest acting inhaled anaesthetic agent at our disposaldand one of the oldest drugs still in routine use in medicine. The combination of its longevity and improvements in the pharmacology of other inhalational and intravenous anaesthetic agents has rendered it prone to criticism in recent decades. As with a number of old drugs, a gap in the evidence base for its use developed over time relative to newer drugs. As a consequence, many critics announced the imminent demise of N 2 O based upon its perceived weaknesses. Data supporting much of this change in attitude to N 2 O have been incomplete or poorly interpreted. Peyton 22 recently commented, 'Over the last two decades, the traditional position where N 2 O was used routinely, except in a relatively small number of defined circumstances, has been supplanted by one where it is rarely used by a new generation of anesthetists at all. In short, there has been a move from "Is there any reason why I shouldn't use N 2 O in this patient?" to "Why should I ever use N 2 O?" This is a rather monolithic attitude to a complex pharmacological and clinical question and, as a specialty; anesthetists are capable of a more sophisticated approach than this'. 22 The current review incorporates new data that fill this gap, indicating that many perceived drawbacks of medical N 2 O administration (e.g. nausea, vomiting, use during laparoscopy, cardiac ischaemia, environmental effects) have been exaggerated or misplaced. There is good reason to maintain interest in the contribution of N 2 O to general anaesthesia and its use as a sedative and analgesic. Rather than jettisoning N 2 O entirely, a more rational approach is its targeted use considering its risk/benefit ratio in any given patient, as should be applied to any drug. We recommend that the supply of N 2 O in hospitals be maintained while encouraging its economic use employing modern low flow delivery systems. Future research into its potential novel applications in prevention or treatment of chronic conditions in specific subpopulations should be pursued in the developing era of precision medicine. 
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